Compare KRYS & ALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | ALK |
|---|---|---|
| Founded | 2015 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.4B |
| IPO Year | 2017 | 2003 |
| Metric | KRYS | ALK |
|---|---|---|
| Price | $249.97 | $38.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $297.60 | $70.09 |
| AVG Volume (30 Days) | 260.2K | ★ 3.7M |
| Earning Date | 05-18-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 6.84 | 0.83 |
| Revenue | $389,130,000.00 | ★ $10,426,000,000.00 |
| Revenue This Year | $40.88 | $8.70 |
| Revenue Next Year | $35.16 | $6.14 |
| P/E Ratio | ★ $36.15 | $45.68 |
| Revenue Growth | ★ 33.94 | 8.09 |
| 52 Week Low | $123.03 | $37.53 |
| 52 Week High | $298.30 | $65.35 |
| Indicator | KRYS | ALK |
|---|---|---|
| Relative Strength Index (RSI) | 39.69 | 27.08 |
| Support Level | $233.64 | N/A |
| Resistance Level | $293.60 | $54.08 |
| Average True Range (ATR) | 9.00 | 2.57 |
| MACD | -2.10 | -1.32 |
| Stochastic Oscillator | 14.28 | 4.15 |
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Alaska Air Group Inc operates two airlines, Alaska and Horizon, in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements. The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary, and Mileage Plan passenger revenue.